Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM.
Dupré
J
J
Behme
M T
MT
Hramiak
I M
IM
McDonald
T J
TJ
D000328:Adult; D001786:Blood Glucose / Q000032:analysis* / Q000378:metabolism; D002096:C-Peptide / Q000097:blood / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005934:Glucagon / Q000097:blood / Q000378:metabolism; D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010191:Pancreatic Polypeptide / Q000097:blood / Q000378:metabolism; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D001786:Blood Glucose; D002096:C-Peptide; D007004:Hypoglycemic Agents; D007328:Insulin; D010446:Peptide Fragments; C055453:glucagon-like peptide 1 (7-36)amide; D010191:Pancreatic Polypeptide; D004763:Glucagon-Like Peptides; D052216:Glucagon-Like Peptide 1; D005934:Glucagon